Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962773 | 0.82 | SMN1; SMN2 (0.52) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL1962776 | 0.79 | MAOB (0.52) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL18526954 | 0.78 | MAOB (0.56) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL12532252 | 0.77 | NPC1 (0.60) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL15619542 | 0.76 | ESR1 (0.50) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL1930256 | 0.74 | NPC1 (0.50) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL10552882 | 0.73 | MAPT (0.47) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL10432798 | 0.73 | MAPT (0.50) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29183304 | 0.73 | NPC1 (0.53) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL11565253 | 0.72 | LMNA (0.50) | NPC1RAB9AMAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10058582-B2 | Therapeutic molecules and deviates for CRC | ANTARTINA LLC (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3337493-A1 | NEW THERAPEUTIC MOLECULES & DEVIATES FOR CRC | Antartina LLC (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017031054-A1 | NEW THERAPEUTIC MOLECULES & DEVIATES FOR CRC | ANTARTINA LLC (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170049839-A1 | Therapeutic molecules & deviates for CRC | NEOCAGE SL (AD) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10058582-B2 | Therapeutic molecules and deviates for CRC | DLD, APC, SEPTIN7 | NPC1 228/4885RAB9A 1199/4885MAPT 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.